Harmony Biosciences (HRMY) Acquires Epygenix Therapeutics, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets
April 30, 2024 7:00 AM EDTLead Candidate, EPX-100, Holds Orphan Drug and Rare Pediatric Disease Designations
EPX-100 in Pivotal Registrational Trial for Dravet Syndrome; Topline Data Expected in 2026
Plan to Initiate Phase 3 Trial for Lennox-Gastaut Syndrome in Second Half of 2024
Potential Billion Dollar Plus Market Opportunity in Rare Epilepsy
PLYMOUTH MEETING, Pa., April 30, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY), today announced the acquisition of... More
